EDITORIAL
Editorial response to Aimo et al Quality-of-life assessment in amyloid transthyretin amyloidosis
Aaron Yarlas,
Corresponding Author
Aaron Yarlas
QualityMetric, Johnston, RI, USA
Correspondence
Aaron Yarlas, QualityMetric, 1301 Atwood Avenue, Suite 216E, Johnston, RI 02919, USA.
Email: [email protected]
Search for more papers by this author
Aaron Yarlas,
Corresponding Author
Aaron Yarlas
QualityMetric, Johnston, RI, USA
Correspondence
Aaron Yarlas, QualityMetric, 1301 Atwood Avenue, Suite 216E, Johnston, RI 02919, USA.
Email: [email protected]
Search for more papers by this author
First published: 26 July 2021
No abstract is available for this article.
REFERENCES
- 1Aimo A, Rapezzi C, Perfetto F, et al. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. Eur J Clin Invest. 2021:e13598. https://doi.org/10.1111/eci.13598
- 2Maruish ME. User's Manual for the SF-36v2 Health Survey. 3rd ed. QualityMetric Incorporated; 2011.
- 3Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379(1): 22-31. https://doi.org/10.1056/NEJMoa1716793
- 4Coelho T, Yarlas A, Waddington-Cruz M, et al. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol. 2020; 267(4): 1070-1079. https://doi.org/10.1007/s00415-019-09671-9
- 5Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019; 60(2): 169-175. https://doi.org/10.1002/mus.26515
